CN103316352A - Graphene oxide nano-drug carrier and anti-tumor drug as well as preparation method of anti-tumor drug - Google Patents
Graphene oxide nano-drug carrier and anti-tumor drug as well as preparation method of anti-tumor drug Download PDFInfo
- Publication number
- CN103316352A CN103316352A CN2013102571879A CN201310257187A CN103316352A CN 103316352 A CN103316352 A CN 103316352A CN 2013102571879 A CN2013102571879 A CN 2013102571879A CN 201310257187 A CN201310257187 A CN 201310257187A CN 103316352 A CN103316352 A CN 103316352A
- Authority
- CN
- China
- Prior art keywords
- pyrenyl
- polyethylene glycol
- graphene oxide
- graphene
- pharmaceutical carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 129
- 229910021389 graphene Inorganic materials 0.000 title claims abstract description 129
- 239000003937 drug carrier Substances 0.000 title claims abstract description 63
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 43
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 69
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 62
- IVCXPKNSONVWNU-UHFFFAOYSA-N 1-(pyren-1-yldisulfanyl)pyrene Chemical group C1=C2C(SSC=3C4=CC=C5C=CC=C6C=CC(C4=C65)=CC=3)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 IVCXPKNSONVWNU-UHFFFAOYSA-N 0.000 claims abstract description 51
- 230000000694 effects Effects 0.000 claims abstract description 42
- 239000002105 nanoparticle Substances 0.000 claims abstract description 30
- 125000001725 pyrenyl group Chemical group 0.000 claims abstract description 12
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 claims description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 72
- 239000003814 drug Substances 0.000 claims description 49
- 230000002209 hydrophobic effect Effects 0.000 claims description 36
- 230000000259 anti-tumor effect Effects 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 31
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 21
- 229940099500 cystamine Drugs 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- -1 1-ethyl-(3-dimethylaminopropyl) Chemical group 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical group C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 13
- 229930195573 Amycin Natural products 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 10
- 229920001427 mPEG Polymers 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- QXYRRCOJHNZVDJ-UHFFFAOYSA-N 4-pyren-1-ylbutanoic acid Chemical compound C1=C2C(CCCC(=O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 QXYRRCOJHNZVDJ-UHFFFAOYSA-N 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 4
- 230000011987 methylation Effects 0.000 claims description 4
- 238000007069 methylation reaction Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 13
- 229960003180 glutathione Drugs 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000008901 benefit Effects 0.000 description 8
- 235000003969 glutathione Nutrition 0.000 description 7
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000002228 disulfide group Chemical group 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000446313 Lamella Species 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a graphene oxide drug carrier and an anti-tumor drug as well as a preparation method of the anti-tumor drug. The graphene oxide drug carrier comprises multiple nano-particles, wherein each nano-particle comprises an inner core formed by graphene oxide and a shell formed by pyrenyl disulfide group polyethylene glycol, and the pyrenyl disulfide group polyethylene glycol is adhered to the surface of the graphene oxide through the pi-pi conjugative effect of pyrenyl and the graphene oxide. The modification effect of the pyrenyl disulfide group polyethylene glycol ensures that the graphene oxide drug carrier has the characteristics of relatively high space stability, electrostatic stability and has relatively high stability.
Description
Technical field
The present invention relates to the pharmaceutical carrier technical field, particularly relate to a kind of graphene oxide pharmaceutical carrier, antitumor drug and preparation method thereof.
Background technology
Graphene oxide has the characteristics that toxicity is low, surface energy is big and can be applied to biomedicine field as pharmaceutical carrier.Graphene oxide has the unrivaled advantage of other carriers as pharmaceutical carrier, for example, utilizes the character of graphene oxide self can carry out the photo-thermal treatment.The general relatively pharmaceutical carrier of simultaneous oxidation Graphene pharmaceutical carrier, its drug loading is also big a lot of with respect to the former.But also there is self defective in graphene oxide as pharmaceutical carrier, and the graphene oxide that does not have a modified stable very poor in human body reunited easily, can not be completely by the metabolism of organism institute.
Summary of the invention
Based on this, be necessary the graphene oxide pharmaceutical carrier that provides a kind of stability higher.
A kind of antitumor drug that comprises this graphene oxide pharmaceutical carrier and preparation method thereof further is provided.
A kind of stannic oxide/graphene nano pharmaceutical carrier comprises a plurality of nano-particle, and each nano-particle comprises the kernel that is formed by graphene oxide and the shell that is formed by pyrenyl disulfide group Polyethylene Glycol; Wherein, described pyrenyl disulfide group Polyethylene Glycol adheres to the surface of described graphene oxide by the π-pi-conjugated effect of pyrenyl and graphene oxide.
Among embodiment, the mass ratio of described graphene oxide and pyrenyl disulfide group Polyethylene Glycol is 1～2:10 therein.
Among embodiment, the particle diameter of described nano-particle is 70～100 nanometers therein.
A kind of antitumor drug comprises hydrophobic medicine and above-mentioned stannic oxide/graphene nano pharmaceutical carrier with antitumor curative effect, and described medicine is carried on the kernel of described stannic oxide/graphene nano pharmaceutical carrier by hydrophobic interaction.
Among embodiment, the mass ratio of described medicine and described stannic oxide/graphene nano pharmaceutical carrier is 1:11～12 therein.
Among embodiment, described medicine is amycin, paclitaxel or camptothecine therein.
A kind of preparing anti-tumor medicine method comprises the steps:
With graphene oxide, pyrenyl disulfide group Polyethylene Glycol and hydrophobic medicine with antitumor curative effect are added to the water and obtain mixture, with described mixture supersound process 2 hours under room temperature, filter, obtain antitumor drug after the lyophilizing, described antitumor drug comprises stannic oxide/graphene nano pharmaceutical carrier and hydrophobic medicine with antitumor curative effect, described stannic oxide/graphene nano pharmaceutical carrier comprises a plurality of nano-particle, and each nano-particle comprises the kernel that formed by graphene oxide and adheres to the shell that the surface of described kernel forms by pyrenyl disulfide group Polyethylene Glycol; Wherein, the surface that the π-pi-conjugated effect of described pyrenyl disulfide group Polyethylene Glycol by pyrenyl and graphene oxide adheres to described graphene oxide forms shell, and described hydrophobic medicine with antitumor curative effect is carried on the kernel of described stannic oxide/graphene nano pharmaceutical carrier by hydrophobic interaction.
Among embodiment, the mass ratio of described graphene oxide, pyrenyl disulfide group Polyethylene Glycol and medicine is 1～2:10:1 therein.
Among embodiment, in the described mixture, the concentration of described graphene oxide is 0.1～1mg/mL therein.
Among embodiment, described pyrenyl disulfide group Polyethylene Glycol prepares as follows therein:
By solid-to-liquid ratio 0.17g:88mg:30mL cystamine hydrochlorate and sodium hydroxide are added to the water and obtain first mixture, described first mixture was stirred under room temperature 30 minutes, revolve to steam in 45 ℃ of following vacuum again and dewater, add methylene chloride then and add in first mixture after described the dewatering, remove by filter precipitation, revolve in 30 ℃ of vacuum again and steam except dichloromethane, obtain cystamine;
Obtain second mixture by solid-to-liquid ratio 120mg:28mg:1g:30mL mixing 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate, N-maloyl imines, carboxy methylation methoxy poly (ethylene glycol) and dichloromethane, with the reaction after 5 hours in nitrogen atmosphere, under the room temperature of described second mixture, in described reacted second mixture, splash into described cystamine, under room temperature, reacted 24 hours again, obtain Polyethylene Glycol and the amino chemical compound that is connected to form by disulfide bond;
By solid-to-liquid ratio 288mg:287mg:178mg:20mL pyrene butanoic acid, 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate, N-maloyl imines and dichloromethane are mixed and to be incorporated under the room temperature reaction 2 hours, add described Polyethylene Glycol and the amino chemical compound that is connected to form by disulfide bond then, reaction is 24 hours under room temperature, obtains described pyrenyl disulfide group Polyethylene Glycol.
Above-mentioned graphene oxide pharmaceutical carrier comprises a plurality of nano-particle, and each nano-particle comprises the kernel that is formed by graphene oxide and the shell that is formed by pyrenyl disulfide group Polyethylene Glycol.Wherein, pyrenyl disulfide group Polyethylene Glycol adheres to the surface formation hydrophilic outer shell of graphene oxide by the π-pi-conjugated effect of pyrenyl and graphene oxide, the modification of pyrenyl disulfide group Polyethylene Glycol makes this graphene oxide pharmaceutical carrier possess higher spatial stability, the characteristics of electrostatic stabilization, and stability is higher.
Description of drawings
Fig. 1 is atomic force microscope (AFM) comparison diagram of the stannic oxide/graphene nano pharmaceutical carrier of graphene oxide and an embodiment;
Fig. 2 is the lamella degree of contrast figure of the stannic oxide/graphene nano pharmaceutical carrier of graphene oxide and an embodiment;
Fig. 3 be an embodiment antitumor drug engulf and discharge schematic diagram intracellular;
There is the release profiles under the environment of environment and no glutathion in Fig. 4 at glutathion for the antitumor drug of embodiment 1.
The specific embodiment
For above-mentioned purpose of the present invention, feature and advantage can be become apparent more, below in conjunction with accompanying drawing the specific embodiment of the present invention is described in detail.A lot of details have been set forth in the following description so that fully understand the present invention.But the present invention can implement much to be different from alternate manner described here, and those skilled in the art can do similar improvement under the situation of intension of the present invention, so the present invention is not subjected to the restriction of following public concrete enforcement.
The stannic oxide/graphene nano pharmaceutical carrier of one embodiment comprises a plurality of nano-particle, and each nano-particle comprises the kernel that formed by graphene oxide and adheres to the shell that the surface of kernel forms by pyrenyl disulfide group Polyethylene Glycol.This nano-particle in the form of sheets.
Pyrenyl disulfide group Polyethylene Glycol is by pyrene butanoic acid, cystamine hydrochlorate and carboxy methylation methoxy poly (ethylene glycol) (mPEG-COOH) reaction, form the pyrenyl disulfide group and pyrenyl linked to each other with disulfide group, the pyrenyl disulfide group is connected in the chemical compound that forms on the Polyethylene Glycol by disulfide group, is expressed as pyrene-S-S-PEG.
Pyrenyl disulfide group Polyethylene Glycol adheres to the surface formation hydrophilic outer shell of graphene oxide by the π-pi-conjugated effect of pyrenyl and graphene oxide.
Pyrenyl disulfide group Polyethylene Glycol is coated on inside with the graphene oxide of less stable, make this graphene oxide pharmaceutical carrier have the advantage that biocompatibility height, toxicity are low, drug loading is high of graphene oxide, the shortcoming of graphene oxide poor stability be can overcome again, biocompatibility height, stable high nano-medicament carrier obtained.This stannic oxide/graphene nano pharmaceutical carrier has higher spatial stability and electrostatic stabilization, and long circulating half-life.
Polyethylene Glycol (PEG) is positioned at the surface of nano-particle.The Polyethylene Glycol nano-particle has good biocompatibility, biodegradation is controlled and catabolite toxicity is low advantage, further makes this stannic oxide/graphene nano pharmaceutical carrier have higher biocompatibility.
Pyrene-S-S-PEG makes this stannic oxide/graphene nano pharmaceutical carrier can avoid immune identification with the formation hydrophilic outer shell that π-pi-conjugated effect adheres to the surface of graphene oxide, when using the carrier loaded medicine of this stannic oxide/graphene nano, can strengthen the half-life of drug system circulation, improve curative effect.
And graphene oxide forms the higher kernel of hydrophobicity, can pass through hydrophobic interaction load hydrophobic drug.
Preferably, the mass ratio of graphene oxide and pyrenyl disulfide group Polyethylene Glycol is 1～2:10, when guaranteeing that above-mentioned stannic oxide/graphene nano pharmaceutical carrier has advantages of higher stability, can give full play to the bigger advantage of graphene oxide drug loading and Polyethylene Glycol and be easy to the advantage that realizes that targeting control discharges.
Each nano-particle of above-mentioned stannic oxide/graphene nano pharmaceutical carrier is kernel with the graphene oxide, the pyrenyl of pyrene-S-S-PEG forms hydrophilic outer shell by the surface that π-pi-conjugated effect adheres to graphene oxide, containing under the aqueous environments of Reducing agent, this π-pi-conjugated effect disappears and the kernel of this stannic oxide/graphene nano pharmaceutical carrier is separated with shell, hydrophobic drug release.Above-mentioned stannic oxide/graphene nano pharmaceutical carrier has the reduction response, is easy to realize that the targeting of medicine discharges.
Preferably, be that kernel, pyrenyl disulfide group Polyethylene Glycol are that the particle diameter of the nano-particle of shell is 70～100 nanometers with the graphene oxide.
Fig. 1 is atomic force microscope (AFM) comparison diagram of graphene oxide and above-mentioned stannic oxide/graphene nano pharmaceutical carrier.Wherein, A is atomic force microscope (AFM) figure of graphene oxide, and B is the AFM figure of above-mentioned stannic oxide/graphene nano pharmaceutical carrier.As seen from Figure 1, above-mentioned stannic oxide/graphene nano pharmaceutical carrier is the same with graphene oxide, and particle diameter is little, and surface energy is big.
Fig. 2 is the lamella degree of contrast figure of graphene oxide and above-mentioned stannic oxide/graphene nano pharmaceutical carrier, and wherein, C represents graphene oxide, and D represents above-mentioned stannic oxide/graphene nano pharmaceutical carrier.As seen from Figure 2, the sheet layer height homogeneity of above-mentioned stannic oxide/graphene nano pharmaceutical carrier is better, and the stable higher of above-mentioned stannic oxide/graphene nano pharmaceutical carrier is described.
The antitumor drug of one embodiment comprises above-mentioned stannic oxide/graphene nano pharmaceutical carrier and hydrophobic medicine with antitumor curative effect.Hydrophobic medicine with antitumor curative effect is carried on the graphene oxide kernel of this stannic oxide/graphene nano pharmaceutical carrier by hydrophobic interaction, forms a plurality of antitumor drug nanoparticles.
Preferably, hydrophobic have the medicine of antitumor curative effect and the mass ratio of this graphene oxide is 1:11～12.
Hydrophobic medicine with antitumor curative effect is amycin, paclitaxel or camptothecine.
This antitumor drug is owing to adopt above-mentioned stannic oxide/graphene nano pharmaceutical carrier as carrier loaded hydrophobic medicine with antitumor curative effect, make this antitumor drug have higher spatial stability and electrostatic stabilization, be difficult for reuniting, can be brought into play curative effect by human body institute's metabolism well.Simultaneously this antitumor drug can be avoided immune identification, Xun Huan half-life in vivo, curative effect height.
And this antitumor drug has good biocompatibility, biodegradation is controlled and catabolite toxicity is low advantage.This antitumor drug also has the reduction response, is easy to realize that targeting control discharges.The release principle of this antitumor drug as shown in Figure 3, hydrophobic medicine with antitumor curative effect is example with the amycin, after the administration, this antitumor drug enters blood circulation, amycin does not have release substantially in blood circulation, antitumor drug enters Cytoplasm by endocytosis after arriving tumor locus, stimulate the π-pi-conjugated effect that makes pyrene-S-S-PEG shell and graphene oxide kernel to disappear by the reduction response then, and hydrophilic pyrene-S-S-PEG shell is dissolved in the Cytoplasm, thereby discharge hydrophobic medicine with antitumor curative effect, medicine is better discharged, the performance curative effect at the target spot position.
The preparing anti-tumor medicine method of one embodiment comprises the steps:
Graphene oxide, pyrenyl disulfide group Polyethylene Glycol and hydrophobic medicine with antitumor curative effect be added to the water obtain mixture, with this mixture supersound process 2 hours under room temperature, filter, obtain antitumor drug after the lyophilizing.
Wherein, antitumor drug comprises stannic oxide/graphene nano pharmaceutical carrier and hydrophobic medicine with antitumor curative effect.The stannic oxide/graphene nano pharmaceutical carrier comprises a plurality of nano-particle, and each nano-particle comprises the kernel that formed by graphene oxide and adheres to the shell that the surface of kernel forms by pyrenyl disulfide group Polyethylene Glycol.Wherein, pyrenyl disulfide group Polyethylene Glycol adheres to the surface formation shell of graphene oxide by the π-pi-conjugated effect of pyrenyl and graphene oxide.Hydrophobic medicine with antitumor curative effect is carried on the kernel of stannic oxide/graphene nano pharmaceutical carrier by hydrophobic interaction.
Hydrophobic medicine with antitumor curative effect is amycin, paclitaxel or camptothecine.
Preferably, graphene oxide, pyrenyl disulfide group Polyethylene Glycol and hydrophobic mass ratio with medicine of antitumor curative effect are 1～2:10:1.
When hydrophobic medicine with antitumor curative effect is amycin, because the water solublity of amycin is relatively poor, for the ease of preparation, with doxorubicin hydrochloride as the feedstock production antitumor drug, for in and doxorubicin hydrochloride in hydrochloric acid, in the mixture of graphene oxide, pyrenyl disulfide group Polyethylene Glycol, hydrophobic medicine with antitumor curative effect and water, add triethylamine, with in and hydrochloric acid in the doxorubicin hydrochloride.
The solid-to-liquid ratio of doxorubicin hydrochloride and triethylamine is 1mg:1.5 μ L.
Preferably, in the mixture of graphene oxide, pyrenyl disulfide group Polyethylene Glycol, hydrophobic medicine with antitumor curative effect and water, the concentration of graphene oxide is 0.1～1mg/mL, so that graphene oxide is scattered in the water preferably, avoid graphene oxide to reunite, with preparation good dispersion, antitumor drug that particle diameter is little.
Above-mentioned pyrenyl disulfide group Polyethylene Glycol is by pyrene butanoic acid, cystamine hydrochlorate and carboxy methylation methoxy poly (ethylene glycol) (mPEG-COOH) reaction, form the pyrenyl disulfide group and pyrenyl linked to each other with disulfide group, the pyrenyl disulfide group is connected in the chemical compound that forms on the Polyethylene Glycol by disulfide group.Pyrenyl disulfide group Polyethylene Glycol adopts following method preparation:
By solid-to-liquid ratio 0.17g:88mg:30mL cystamine hydrochlorate and sodium hydroxide are added to the water and obtain first mixture, first mixture was stirred under room temperature 30 minutes, revolve to steam in 45 ℃ of following vacuum again and dewater, in first mixture after the adding that adds methylene chloride then dewaters, remove by filter precipitation, revolve in 30 ℃ of vacuum again and steam except dichloromethane, obtain the weak yellow liquid cystamine.
Obtain second mixture by solid-to-liquid ratio 120mg:28mg:1g:30mL mixing 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (EDCHCl), N-maloyl imines (NHS), methoxy poly (ethylene glycol) carboxylic acid (mPEG-COOH) and dichloromethane, with the reaction after 5 hours in nitrogen atmosphere, under the room temperature of second mixture, in reacted second mixture, splash into the cystamine for preparing, under room temperature, reacted 24 hours again, obtain Polyethylene Glycol and the amino chemical compound that is connected to form by disulfide bond, be expressed as mPEG-S-S-NH
2The mass ratio of cystamine and methoxy poly (ethylene glycol) carboxylic acid (mPEG-COOH) is 0.15:1.
The carboxyl that EDCHCl and NHS are used for activation methoxy poly (ethylene glycol) carboxylic acid (mPEG-COOH) (COOH), to improve the activity of carboxyl, improves reaction rate.
By solid-to-liquid ratio 288mg:287mg:178mg:20mL pyrene butanoic acid, 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (EDCHCl), N-maloyl imines (NHS) and dichloromethane are mixed to be incorporated under the room temperature reaction 2 hours, add 0.5g Polyethylene Glycol and the amino chemical compound (mPEG-S-S-NH that is connected to form by disulfide bond then
2), reaction is 24 hours under room temperature, obtains pyrenyl disulfide group Polyethylene Glycol.
It is 5000 methoxy poly (ethylene glycol) carboxylic acid (mPEG-COOH) that above-mentioned methoxy poly (ethylene glycol) carboxylic acid (mPEG-COOH) is preferably weight average molecular weight.
The employing weight average molecular weight is 5000 methoxy poly (ethylene glycol) carboxylic acid (mPEG-COOH) preparation pyrenyl disulfide group Polyethylene Glycol, with the pyrenyl disulfide group Polyethylene Glycol that obtains for the preparation of the stannic oxide/graphene nano pharmaceutical carrier, and when this carrier is used for the hydrophobic medicine with antitumor curative effect of load and forms antitumor drug, make this antitumor drug in blood circulation, be difficult to other organ picked-up, be beneficial to targeting and discharge, and the particle diameter of this antitumor drug is less.
Method is simple for above-mentioned preparing anti-tumor medicine, and the reaction condition gentleness is convenient to operation and is promoted.
It below is specific embodiment.
Take by weighing 0.17g cystamine hydrochlorate (1.1mmol) and 88mgNaOH(2.2mmol) add in the 30mL water and at room temperature stir 30min, revolve to steam in 45 ℃ of vacuum again and dewater.Dichloromethane adds in the said mixture, has filtered precipitation, and 30 ℃ of vacuum are revolved and steamed except dichloromethane again.Obtain the weak yellow liquid cystamine.Get 120mgEDCHCl (0.62mmol), 28mg NHS (0.23mmol), 1g mPEG-COOH(weight average molecular weight 5000) and 30mL dichloromethane N at room temperature
2Behind the reaction 5h, slowly splash into the 0.15g cystamine in the atmosphere, react 24h more at normal temperatures, obtain Polyethylene Glycol and the amino chemical compound (mPEG-S-S-NH that is connected to form by disulfide bond
2);
Pipette 288mg pyrene butanoic acid, 287mg EDCHCl, 178mgNHS at room temperature activate 2h in the 20mL dichloromethane after, add 0.5g mPEG-S-S-NH
2After, at room temperature react 24h after, obtain pyrenyl disulfide group Polyethylene Glycol;
Pipette the 1mg graphene oxide, 10mg pyrenyl disulfide group Polyethylene Glycol, 1mg doxorubicin hydrochloride (DXR), 1.5 μ L triethylamine, add 10mL water, under the room temperature, with the ultrasonic 2h of ultrasonic carbon-point, allow solvent evaporates during this time, filter then, obtain antitumor drug after the lyophilizing, this antitumor drug comprises stannic oxide/graphene nano pharmaceutical carrier and amycin, the stannic oxide/graphene nano pharmaceutical carrier comprises a plurality of nano-particle, each nano-particle comprises the kernel that formed by graphene oxide and adheres to the shell that the surface of stating kernel forms by pyrenyl disulfide group Polyethylene Glycol that amycin is carried on the kernel by hydrophobic interaction.
Above-mentioned antitumor drug is 5.5 at pH value, the release profiles I in the aqueous solution of the glutathion (GSH) of 0mM/L, be 5.5 at pH value, the release profiles II in the aqueous solution of the glutathion (GSH) of 10mM/L, be 7.4 at pH value, the release profiles III in the aqueous solution of the glutathion (GSH) of 0mM/L and be 7.4 at pH value, the release profiles IV in the aqueous solution of the glutathion (GSH) of 10mM/L as shown in Figure 4.As seen from Figure 4, be respectively 5.5 and at 7.4 o'clock at pH value, above-mentioned antitumor drug can discharge in the aqueous solution of the glutathion (GSH) of 10mM/L preferably, and As time goes on, the amount of the amycin of release increases gradually.
Take by weighing 0.17g cystamine hydrochlorate (1.1mmol) and 88mgNaOH(2.2mmol) add in the 30ml water and at room temperature stir 30min, revolve to steam in 45 ℃ of vacuum again and dewater.Dichloromethane adds in the said mixture, has filtered precipitation, and 30 ℃ of vacuum are revolved and steamed except dichloromethane again.Obtain the weak yellow liquid cystamine.Get 120mgEDCHCl (0.62mmol), 28mgNHS(0.23mmol), 1gmPEG-COOH(weight average molecular weight 5000), 30ml dichloromethane N at room temperature
2In the atmosphere behind the reaction 5h, slowly splash into after the 0.15g cystamine reacts 24h more at normal temperatures, obtain mPEG-S-S-NH
2
Pipette 288mg pyrene butanoic acid, 287mgEDCHCl, 178mgNHS at room temperature activate 2h in the 20ml dichloromethane after, add 0.5gmPEG-S-S-NH
2After, at room temperature react 24h after, obtain pyrene-S-S-PEG.
Pipette the 2mg graphene oxide, 10mg pyrene-S-S-PEG, 1mgDXR, 1.5 μ l triethylamine, add 10ml water, under the room temperature, with the ultrasonic 2h of ultrasonic carbon-point, allow solvent evaporates during this time, filter then, obtain antitumor drug after the lyophilizing, this antitumor drug comprises stannic oxide/graphene nano pharmaceutical carrier and amycin, the stannic oxide/graphene nano pharmaceutical carrier comprises a plurality of nano-particle, each nano-particle comprises the kernel that formed by graphene oxide and adheres to the shell that the surface of stating kernel forms by pyrenyl disulfide group Polyethylene Glycol that amycin is carried on the kernel by hydrophobic interaction.This antitumor drug is containing the GSH(gsh proglumide of 10mM/L) among the PBS of PH=5.5, its reduction stimuli responsive releasing effect is good.
Take by weighing 0.34g cystamine hydrochlorate (2.2mmol) and 176mgNaOH(4.4mmol) add in the 60mL water and at room temperature stir 30min, revolve to steam in 45 ℃ of vacuum again and dewater.Dichloromethane adds in the said mixture, has filtered precipitation, and 30 ℃ of vacuum are revolved and steamed except dichloromethane again.Obtain the weak yellow liquid cystamine.Get 240mgEDCHCl (1.24mmol), 56mg NHS (0.46mmol), 2g mPEG-COOH(weight average molecular weight 5000) and 60mL dichloromethane N at room temperature
2Behind the reaction 5h, slowly splash into the 0.30g cystamine in the atmosphere, react 24h more at normal temperatures, obtain Polyethylene Glycol and the amino chemical compound (mPEG-S-S-NH that is connected to form by disulfide bond
2);
Pipette 288mg pyrene butanoic acid, 287mg EDCHCl, 178mgNHS at room temperature activate 2h in the 20mL dichloromethane after, add 1.0g mPEG-S-S-NH
2After, at room temperature react 24h after, obtain pyrenyl disulfide group Polyethylene Glycol;
Pipette 1mg graphene oxide, 10mg pyrenyl disulfide group Polyethylene Glycol and 1mg paclitaxel and add 10mL water, under the room temperature, with the ultrasonic 2h of ultrasonic carbon-point, allow solvent evaporates during this time, obtain antitumor drug after filtration, the lyophilizing then, this antitumor drug comprises stannic oxide/graphene nano pharmaceutical carrier and paclitaxel, the stannic oxide/graphene nano pharmaceutical carrier comprises a plurality of nano-particle, each nano-particle comprises the kernel that formed by graphene oxide and adheres to the shell that the surface of stating kernel forms by pyrenyl disulfide group Polyethylene Glycol that paclitaxel is carried on the kernel by hydrophobic interaction.
The above embodiment has only expressed several embodiment of the present invention, and it describes comparatively concrete and detailed, but can not therefore be interpreted as the restriction to claim of the present invention.Should be pointed out that for the person of ordinary skill of the art without departing from the inventive concept of the premise, can also make some distortion and improvement, these all belong to protection scope of the present invention.Therefore, the protection domain of patent of the present invention should be as the criterion with claims.
Claims (10)
1. a stannic oxide/graphene nano pharmaceutical carrier is characterized in that, comprises a plurality of nano-particle, and each nano-particle comprises the kernel that is formed by graphene oxide and the shell that is formed by pyrenyl disulfide group Polyethylene Glycol; Wherein, described pyrenyl disulfide group Polyethylene Glycol adheres to the surface of described graphene oxide by the π-pi-conjugated effect of pyrenyl and graphene oxide.
2. stannic oxide/graphene nano pharmaceutical carrier according to claim 1 is characterized in that, the mass ratio of described graphene oxide and pyrenyl disulfide group Polyethylene Glycol is 1～2:10.
3. stannic oxide/graphene nano pharmaceutical carrier according to claim 1 is characterized in that, the particle diameter of described nano-particle is 70～100 nanometers.
4. antitumor drug, it is characterized in that, comprise hydrophobic medicine and each described stannic oxide/graphene nano pharmaceutical carrier of claim 1～3 with antitumor curative effect, described medicine is carried on the kernel of described stannic oxide/graphene nano pharmaceutical carrier by hydrophobic interaction.
5. antitumor drug according to claim 4 is characterized in that, the mass ratio of described medicine and described stannic oxide/graphene nano pharmaceutical carrier is 1:11～12.
6. antitumor drug according to claim 4 is characterized in that, described medicine is amycin, paclitaxel or camptothecine.
7. a preparing anti-tumor medicine method is characterized in that, comprises the steps:
With graphene oxide, pyrenyl disulfide group Polyethylene Glycol and hydrophobic medicine with antitumor curative effect are added to the water and obtain mixture, with described mixture supersound process 2 hours under room temperature, filter, obtain antitumor drug after the lyophilizing, described antitumor drug comprises stannic oxide/graphene nano pharmaceutical carrier and hydrophobic medicine with antitumor curative effect, described stannic oxide/graphene nano pharmaceutical carrier comprises a plurality of nano-particle, and each nano-particle comprises the kernel that formed by graphene oxide and adheres to the shell that the surface of described kernel forms by pyrenyl disulfide group Polyethylene Glycol; Wherein, the surface that the π-pi-conjugated effect of described pyrenyl disulfide group Polyethylene Glycol by pyrenyl and graphene oxide adheres to described graphene oxide forms shell, and described hydrophobic medicine with antitumor curative effect is carried on the kernel of described stannic oxide/graphene nano pharmaceutical carrier by hydrophobic interaction.
8. preparing anti-tumor medicine method according to claim 7 is characterized in that, the mass ratio of described graphene oxide, pyrenyl disulfide group Polyethylene Glycol and medicine is 1～2:10:1.
9. preparing anti-tumor medicine method according to claim 7 is characterized in that, in the described mixture, the concentration of described graphene oxide is 0.1～1mg/mL.
10. preparing anti-tumor medicine method according to claim 7 is characterized in that, described pyrenyl disulfide group Polyethylene Glycol prepares as follows:
By solid-to-liquid ratio 0.17g:88mg:30mL cystamine hydrochlorate and sodium hydroxide are added to the water and obtain first mixture, described first mixture was stirred under room temperature 30 minutes, revolve to steam in 45 ℃ of following vacuum again and dewater, add methylene chloride then and add in first mixture after described the dewatering, remove by filter precipitation, revolve in 30 ℃ of vacuum again and steam except dichloromethane, obtain cystamine;
Obtain second mixture by solid-to-liquid ratio 120mg:28mg:1g:30mL mixing 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate, N-maloyl imines, carboxy methylation methoxy poly (ethylene glycol) and dichloromethane, with the reaction after 5 hours in nitrogen atmosphere, under the room temperature of described second mixture, in described reacted second mixture, splash into described cystamine, under room temperature, reacted 24 hours again, obtain Polyethylene Glycol and the amino chemical compound that is connected to form by disulfide bond;
By solid-to-liquid ratio 288mg:287mg:178mg:20mL pyrene butanoic acid, 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate, N-maloyl imines and dichloromethane are mixed and to be incorporated under the room temperature reaction 2 hours, add described Polyethylene Glycol and the amino chemical compound that is connected to form by disulfide bond then, reaction is 24 hours under room temperature, obtains described pyrenyl disulfide group Polyethylene Glycol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310257187.9A CN103316352B (en) | 2013-06-25 | 2013-06-25 | Stannic oxide/graphene nano pharmaceutical carrier, antitumor drug and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310257187.9A CN103316352B (en) | 2013-06-25 | 2013-06-25 | Stannic oxide/graphene nano pharmaceutical carrier, antitumor drug and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103316352A true CN103316352A (en) | 2013-09-25 |
| CN103316352B CN103316352B (en) | 2018-09-07 |
Family
ID=49185583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310257187.9A Active CN103316352B (en) | 2013-06-25 | 2013-06-25 | Stannic oxide/graphene nano pharmaceutical carrier, antitumor drug and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103316352B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784407A (en) * | 2014-02-26 | 2014-05-14 | 哈尔滨医科大学 | Folic acid-mediated (polyethylene glycol) PEG-graphene oxide doxorubicine-loaded nanoparticle and preparation method thereof |
| CN104826128A (en) * | 2015-04-30 | 2015-08-12 | 中国药科大学 | Polysaccharide modified reduction-sensitive graphene oxide carrier with organism lesion site triggered drug release and preparation and application of pharmaceutical composition thereof |
| CN105999291A (en) * | 2016-04-23 | 2016-10-12 | 上海大学 | Method for improving amount of drug doxorubicin loaded on graphene quantum dots |
| CN106421804A (en) * | 2016-10-21 | 2017-02-22 | 曲阜师范大学 | Fluorinated graphene nanometer medicine carrier, and preparation method and application thereof |
| CN106692975A (en) * | 2016-12-01 | 2017-05-24 | 浙江大学常州工业技术研究院 | Oxidized-graphene nano-drug carrier with targeting function and preparing method thereof |
| CN110973156A (en) * | 2019-11-28 | 2020-04-10 | 自然资源部第三海洋研究所 | Graphene oxide/rosmarinic acid composite material and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274521A (en) * | 2011-08-25 | 2011-12-14 | 天津医科大学 | Graphene oxide-based target gene vector material and preparation and use thereof |
| CN102320599A (en) * | 2011-08-02 | 2012-01-18 | 同济大学 | Method for functionalizing polymer on surface of nano graphene oxide |
| CN102502607A (en) * | 2011-11-10 | 2012-06-20 | 郑州大学 | Method for preparing graphene solution based on supercritical carbon dioxide and pyrenyl polymers |
| CN102585425A (en) * | 2011-12-21 | 2012-07-18 | 青岛大学 | Preparation method of temperature-sensitive controllable graphene-polymer composite material |
-
2013
- 2013-06-25 CN CN201310257187.9A patent/CN103316352B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102320599A (en) * | 2011-08-02 | 2012-01-18 | 同济大学 | Method for functionalizing polymer on surface of nano graphene oxide |
| CN102274521A (en) * | 2011-08-25 | 2011-12-14 | 天津医科大学 | Graphene oxide-based target gene vector material and preparation and use thereof |
| CN102502607A (en) * | 2011-11-10 | 2012-06-20 | 郑州大学 | Method for preparing graphene solution based on supercritical carbon dioxide and pyrenyl polymers |
| CN102585425A (en) * | 2011-12-21 | 2012-07-18 | 青岛大学 | Preparation method of temperature-sensitive controllable graphene-polymer composite material |
Non-Patent Citations (1)
| Title |
|---|
| HUIYUN WEN, ET AL.: "Engineered redox-responsive PEG detachment mechanism in PEGlated nano-graphene oxide for intracellular drug delivery", 《SMALL》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784407A (en) * | 2014-02-26 | 2014-05-14 | 哈尔滨医科大学 | Folic acid-mediated (polyethylene glycol) PEG-graphene oxide doxorubicine-loaded nanoparticle and preparation method thereof |
| CN103784407B (en) * | 2014-02-26 | 2016-01-20 | 哈尔滨医科大学 | Graphene oxide-loaded adriamycin nano-particles of a kind of folate-mediated PEG-and preparation method thereof |
| CN104826128A (en) * | 2015-04-30 | 2015-08-12 | 中国药科大学 | Polysaccharide modified reduction-sensitive graphene oxide carrier with organism lesion site triggered drug release and preparation and application of pharmaceutical composition thereof |
| CN104826128B (en) * | 2015-04-30 | 2018-04-24 | 中国药科大学 | The graphene oxide carrier of polyose modification of organism lesions position triggering drug release and its preparation of pharmaceutical compositions and application |
| CN105999291A (en) * | 2016-04-23 | 2016-10-12 | 上海大学 | Method for improving amount of drug doxorubicin loaded on graphene quantum dots |
| CN106421804A (en) * | 2016-10-21 | 2017-02-22 | 曲阜师范大学 | Fluorinated graphene nanometer medicine carrier, and preparation method and application thereof |
| CN106421804B (en) * | 2016-10-21 | 2019-09-03 | 曲阜师范大学 | A kind of fluorinated graphene nano-medicament carrier and its preparation method and application |
| CN106692975A (en) * | 2016-12-01 | 2017-05-24 | 浙江大学常州工业技术研究院 | Oxidized-graphene nano-drug carrier with targeting function and preparing method thereof |
| CN110973156A (en) * | 2019-11-28 | 2020-04-10 | 自然资源部第三海洋研究所 | Graphene oxide/rosmarinic acid composite material and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103316352B (en) | 2018-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103316352A (en) | Graphene oxide nano-drug carrier and anti-tumor drug as well as preparation method of anti-tumor drug | |
| Huang et al. | Phthalocyanine-based coordination polymer nanoparticles for enhanced photodynamic therapy | |
| CN101254309A (en) | Folacin receptor mediated targeted acetyl pullulan polysaccharide nano granule and preparation thereof | |
| CN103251561B (en) | Double-sensitive disintegrating nano-sized vesica medicine carrier preparation and preparation method thereof | |
| CN101708162A (en) | Nanoparticle and preparation method thereof | |
| CN104162169B (en) | A kind of preparation method of pharmaceutical composition | |
| CN109010846A (en) | Polyethylene glycol-chitosan-curcumin polymer and its medicine-carried nano particles and preparation method | |
| CN104840977A (en) | Method for preparing magnetic fluorescence composite nano drug carrier | |
| CN111870579B (en) | Tumor-targeted nano micelle, preparation method and application of nano micelle as drug carrier | |
| CN103193944A (en) | Amphiphilic polymer with tumor targeting property and visible light degradability and medicament carrier as well as preparation method thereof | |
| CN103446588B (en) | Targeting type diagnosis and treatment coupling medicine and its preparation method and application | |
| CN109846857B (en) | Preparation method and application of active natural supramolecular photosensitizer | |
| CN108969480A (en) | A kind of near infrared light responsiveness light moves controlled drug delivery system and preparation method thereof | |
| Wang et al. | Tunable Zeolitic Imidazolate Framework‐8 Nanoparticles for Biomedical Applications | |
| CN103239718B (en) | Method for preparing adriamycin-loaded polycaprolactone-block-polyethylene glycol nano microspheres | |
| CN105327362B (en) | A kind of preparation method of the graphene targetable drug carriers of amphipathic nature polyalcohol brush modification | |
| CN108395543B (en) | Modified polyrotaxane, medicine-carrying micelle based on polyrotaxane and preparation method and application of medicine-carrying micelle | |
| CN104434792A (en) | Polymer micelle, preparation method thereof, antitumor pharmaceutical composition, preparation and preparation method thereof | |
| CN105055322A (en) | Preparation methods of methotrexate and lecithin compound, nano-particles of methotrexate and lecithin compound as well as targeted sustained release preparation of methotrexate and lecithin compound | |
| CN109908358B (en) | Ursolic acid polymer drug-loaded nanoparticle and preparation method and application thereof | |
| CN109265658B (en) | Drug-loaded nanoparticle based on ferulic acid polymer and preparation method and application thereof | |
| CN110917349A (en) | Bowl-shaped ISP (internet service provider) composite functional nano particle as well as preparation method and application thereof | |
| JP5201763B2 (en) | Method for producing mixed fine particle capsules comprising particles having different average particle sizes | |
| CN102525936A (en) | Compound epirubicin hydrochloride polylactic-co-glycolic acid (PLGA) nanoparticles and preparation method thereof | |
| CN101112361B (en) | Magnetic nanometer particulate of liposoluble photosensitizer and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240116 Address after: Room a-207, office building, Shenzhen Institute of advanced technology, Chinese Academy of Sciences, 1068 Xueyuan Avenue, Shenzhen University Town, Nanshan District, Shenzhen, Guangdong 518055 Patentee after: Shenzhen advanced science and technology Cci Capital Ltd. Address before: 1068 No. 518055 Guangdong city in Shenzhen Province, Nanshan District City Xili University School Avenue Patentee before: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240423 Address after: Floor 8, No. 229, Gongchang Road, Zhenmei Community, Xinhu Street, Guangming District, Shenzhen, Guangdong 518000 Patentee after: Shenzhen Biological Manufacturing Industry Innovation Center Co.,Ltd. Country or region after: China Address before: Room a-207, office building, Shenzhen Institute of advanced technology, Chinese Academy of Sciences, 1068 Xueyuan Avenue, Shenzhen University Town, Nanshan District, Shenzhen, Guangdong 518055 Patentee before: Shenzhen advanced science and technology Cci Capital Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |